- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Vor Biopharma: Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update | 185 | GlobeNewswire (Europe) | Multiple Late-Stage Data Readouts Reinforce Telitacicept's Broad Potential Across Autoimmune DiseasesExpansion of Executive Leadership and Board Strengthens Global Development Capabilities Expected... ► Artikel lesen | |
| Mi | Vor Biopharma Inc. - 8-K, Current Report | - | SEC Filings | ||
| VOR BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 11.11. | Vor Biopharma Stock Sinks 48% | 7 | RTTNews | ||
| 11.11. | Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial | 12 | Benzinga.com | ||
| 11.11. | Vor Biopharma slumps 26%, prices $100M equity at $10 per share | 1 | Seeking Alpha | ||
| 11.11. | Vor Biopharma Prices Public Offering Of 10 Mln Shares At $10.00/shr | 3 | RTTNews | ||
| 11.11. | Vor Bio prices $100 million public offering of common stock | 5 | Investing.com | ||
| 11.11. | Vor Biopharma: Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock | 128 | GlobeNewswire (Europe) | BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the... ► Artikel lesen | |
| 10.11. | Vor Bio launches $100 million common stock offering | 1 | Investing.com | ||
| 10.11. | Vor Bio launches $100M public stock offering | 2 | Seeking Alpha | ||
| 08.11. | Vor Bio's IgA nephropathy drug shows 55% reduction in proteinuria | 2 | Investing.com | ||
| 08.11. | Vor Bio: Medikament gegen IgA-Nephropathie reduziert Proteinurie um 55 % | 10 | Investing.com Deutsch | ||
| 08.11. | Vor Biopharma: Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China | 85 | GlobeNewswire (Europe) | Treatment with telitacicept for 39 weeks resulted in a rapid, clinically meaningful, and statistically significant reduction in proteinuria, with a favorable safety profile Telitacicept demonstrated... ► Artikel lesen | |
| 03.11. | Vor Biopharma Appoints Jeremy Sokolove As New Chief Medical Officer | 3 | RTTNews | ||
| 03.11. | Vor Bio appoints Jeremy Sokolove as chief medical officer | 2 | Investing.com | ||
| 31.10. | Vor Biopharma: Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 29.10. | Vor Biopharma: Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data | 139 | GlobeNewswire (Europe) | Telitacicept delivered consistent quality-of-life improvement across both treatment and placebo crossover arms 100% of patients on telitacicept for 48 weeks achieved =2-point Myasthenia Gravis Activities... ► Artikel lesen | |
| 28.10. | Vor Biopharma Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.10. | Vor Biopharma: Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren's Disease | 2 | GlobeNewswire (USA) | ||
| 17.10. | Vor Biopharma: Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology's Kidney Week 2025 | 170 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data... ► Artikel lesen |
1 2 3 4 5 Weiter >>
93 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EDITAS MEDICINE | 2,237 | +0,27 % | Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y | ||
| SOL GLOBAL INVESTMENTS | 0,026 | +10,82 % | SOL Global Investments Corp.: SOL Global Announces Change of Auditor | Toronto, Ontario--(Newsfile Corp. - October 15, 2025) - SOL Global Investments Corp. (CSE: SOL) (OTCID: SOLCF) (FSE: 9SB) ("SOL Global" or the "Company") today announce that it has changed its auditor... ► Artikel lesen | |
| TRINITY BIOTECH | 0,823 | -7,76 % | Trinity Biotech plc: Trinity Biotech Secures Major Regulatory Approval for Offshored and Outsourced Manufacturing of Its Market Leading Uni-Gold Rapid HIV Test, Further Accelerating Financial Performance Transformation | DUBLIN, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable... ► Artikel lesen | |
| FATE THERAPEUTICS | 0,836 | -1,28 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates | Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient Enrollment of FT819, an Off-the-Shelf CD19-targeted CAR T-cell Product Candidate... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 6,620 | -1,93 % | Arcturus Therapeutics Holdings Inc. - 10-Q, Quarterly Report | ||
| OVID THERAPEUTICS | 1,140 | +0,88 % | Ovid Therapeutics Inc.: Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results | Meg Alexander appointed Chief Executive Officer effective January 1, 2026; Dr. Jeremy M. Levin to transition to Executive Chair of the Board of DirectorsNext-generation GABA-aminotransferase (GABA-AT)... ► Artikel lesen | |
| EQUILLIUM | 0,996 | +9,33 % | Equillium, Inc. - 8-K, Current Report | ||
| GENERATION BIO | 5,290 | -2,94 % | Generation Bio Co.: Generation Bio Announces CEO Transition | • Geoff McDonough, MD to step down as CEO & President and become Chair of the Company's Board of Directors • Current Chief Legal Officer Yalonda Howze, JD named Interim CEO & President CAMBRIDGE,... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 10,060 | -8,17 % | 4D Molecular Therapeutics, Inc.: 4DMT Appoints Kristian Humer as Chief Financial Officer | EMERYVILLE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted... ► Artikel lesen | |
| REGENCELL BIOSCIENCE | 13,320 | +2,78 % | Regencell Bioscience Holdings Limited Announces Forward Stock Split | HONG KONG, June 2, 2025 - Regencell Bioscience Holdings Limited (Nasdaq: RGC) (the "Company"), today announced that its board of directors approved a 38-for-one forward stock split to be paid in the... ► Artikel lesen | |
| CABALETTA BIO | 2,335 | -2,30 % | Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update | Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable safety profile for autoimmune patients supporting outpatient... ► Artikel lesen | |
| LONGEVERON | 0,640 | -1,33 % | Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy | The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammagingNo approved... ► Artikel lesen | |
| PROKIDNEY | 2,275 | +0,66 % | PROKIDNEY CORP. Q3 Loss Decreases, Beats Estimates | ||
| ATHIRA PHARMA | 4,600 | +1,77 % | Athira Pharma, Inc.: Athira Pharma Announces Reverse Stock Split | BOTHELL, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. ("Athira" or "Company") (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore... ► Artikel lesen | |
| BOLT PROJECTS | 1,650 | +2,48 % | Bolt Projects Holdings GAAP EPS of -$2.70, revenue of $0.37M |
Das Unternehmen VOR BIOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -9,17 % bei einem Aktienkurs von 9,110 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VOR BIOPHARMA INC finden Sie auf Wallstreet Online.